Multifunctional Nanoassembly for MRI-Trackable Dendritic Cell Dependent and Independent Photoimmunotherapy.

Area of Science:

• Oncology
• Nanomedicine
• Immunology

Background:

• Current immunotherapies struggle with tumors exhibiting low antigenicity and immunosuppressive tumor microenvironments (TME).
• Effective cancer treatment requires strategies to overcome these challenges and enhance immune responses.
• Novel nanomedicines are needed to improve antigen presentation and modulate the TME.

Purpose of the Study:

• To develop a multifunctional nanoassembly (FMMC) for enhanced cancer immunotherapy and theranostics.
• To investigate FMMC's ability to improve tumor antigenicity and reverse TME immunosuppression.
• To evaluate FMMC's efficacy in combination with phototherapy and its potential for MRI monitoring.

Main Methods:

• Self-assembly of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor prodrug (FM), Ce6, and manganese ions (Mn2+) into FMMC.
• Laser-triggered FMMC treatment to induce immunogenic cell death and activate STING/MHC-I signaling.
• Assessment of T cell responses, TME modulation, PD-L1 expression, and MRI capabilities.

Main Results:

• FMMC treatment effectively induced immunogenic cell death and sculpted tumor antigenicity.
• FMMC inhibited IDO-1, leading to TME reversion from immunosuppressive to immunoactivated.
• FMMC-based phototherapy upregulated PD-L1, enhancing sensitivity to anti-PD-1 therapy, and improved MRI contrast for tumor monitoring.

Conclusions:

• FMMC acts as a potent immune nanosculptor, reprogramming immunosuppressive tumors and TME.
• The nanoassembly demonstrates significant anticancer efficacy and theranostic capabilities.
• FMMC shows promise for advanced cancer theranostics, combining immunotherapy, phototherapy, and MRI monitoring.